Drug Trial Radar · NCT03603548
Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial
Last checked: Nov 20, 2026Latest source record: Jul 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 9, 2018
Primary completion
Jul 9, 2023
Study completion Jul 9, 2023
Sponsor
- Lead sponsor
- Medical University of WarsawAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adult patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after orthotropic liver transplantation (OLTx) on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
Conditions
- Liver Transplant Rejection
- Immunosuppression
Interventions
EnvarsusDrug
Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
AdvagrafDrug
Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
Primary outcomes
What the sponsor says the trial is designed to measure.
- acute rejectionTime frame: 12 months
- chronic rejectionTime frame: 5 years
- tremorTime frame: 12 months
- de novo diabetesTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Warsaw Medical University
Warsaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.